Protein–Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection
Errikos Petsas, Despoina P. Kiouri, Nikitas Georgiou, Gerasimos Siasos, Thomas Mavromoustakos, Christos T. Chasapis
TL;DR
This review explores how specific proteins involved in heart and metabolic diseases interact with drugs, aiming to improve weight loss and heart protection through better drug design.
Contribution
The paper provides structural insights into six cardiometabolic drug targets to guide the design of multi-target ligands for integrated therapeutic effects.
Findings
Dual GLP-1R/GIPR agonists like tirzepatide show improved glycemic control and weight reduction.
Inhibiting PCSK9, NF-κB, and NLRP3 reduces cholesterol and inflammation, offering cardioprotection.
Structural analysis reveals complementary motifs that can guide the development of next-generation multi-target ligands.
Abstract
Cardiometabolic diseases (CVDs) are the leading cause of premature mortality and disability worldwide, arising from of cardiovascular and metabolic dysregulation. This review focuses on six critical therapeutic targets established in cardiometabolic regulation: GLP-1R, GIPR, FGFR1/β-Klotho, PCSK9, NF-κB, and the NLRP3 inflammasome. Drawing on curated structural datasets, we analyze the mechanisms of action and map key binding domain features that govern ligand efficacy and specificity. Dual GLP-1R/GIPR agonists, such as tirzepatide, demonstrate superior outcomes in glycemic control and weight reduction. Concurrently, inhibiting PCSK9, NF-κB, and NLRP3 helps to lower cholesterol and reduce harmful inflammation, offering cardioprotection. Structural analysis across these targets reveals complementary motifs (aromatic, hydrophobic, and polar residues). These insights guide the rational…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Figure 14
Figure 15
Figure 16
Figure 17
Figure 18
Figure 19
Figure 20
Figure 21
Figure 22
Figure 23
Figure 24
Figure 25
Figure 26
Figure 27
Figure 28
Figure 29
Figure 30
Figure 31
Figure 32
Figure 33Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsFibroblast Growth Factor Research · Diabetes Treatment and Management · Parathyroid Disorders and Treatments